Genetic Disease and HR - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Genetic Disease

How Has COVID-19 Changed the Way We Work in the Life Sciences?

XTalks

SEPTEMBER 29, 2021

Xtalks spoke with two HR professionals to find out how companies are handling the transition from a work-from-home policy to a hybrid or back-to-work model. Additionally, these life science companies are now trying to find the new normal for many of their employees to accommodate the new lifestyle they have embraced.

Life Science

Life Science HR Scientist Genetic Disease

FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1

The Pharma Data

NOVEMBER 24, 2020

PH1 is an ultra-rare genetic disease characterized by oxalate overproduction. 0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 About Primary Hyperoxaluria Type 1 (PH1) PH1 is an ultra-rare genetic disease that affects an estimated one to three individuals per million in the United States and Europe.

FDA Approval

FDA Approval Production RNA Medicine

How Has COVID-19 Changed the Way We Work in the Life Sciences?

FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1

Stay Connected